
Researchers from the LFB USA Inc. in Framingham, Mass. engineered rabbits and raised them in order to produce milk with the blood clotting factor VII (FVII) agent for use in human patients with hemophilia.

Researchers from the LFB USA Inc. in Framingham, Mass. engineered rabbits and raised them in order to produce milk with the blood clotting factor VII (FVII) agent for use in human patients with hemophilia.

All von Willebrand Disease patients successfully managed bleeding episode using BAX 111 treatment, according to a study conducted by Baxalta. The study was published in the journal Blood.